Immunosuppressive effects of erythropoietin on human alloreactive T cells

Journal of the American Society of Nephrology

Volumn 25, Issue 9, 2014, Pages 2003-2015

  Cravedi, Paolo ^a   Manrique, Joaquin ^a   Hanlon, Katherine E ^a   Reid Adam, Jessica ^a   Brody, Joshua ^a   Prathuangsuk, Praeophayom ^a   Mehrotra, Anita ^a   Heeger, Peter S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD131 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HLA ANTIGEN CLASS 2; INTERLEUKIN 2 RECEPTOR; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C GAMMA1; PROTEIN KINASE B; PROTEIN KINASE ZAP 70; STAT1 PROTEIN; STAT6 PROTEIN; T LYMPHOCYTE RECEPTOR; ALLOANTIGEN; CSF2RB PROTEIN, HUMAN; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ADOPTIVE TRANSFER; ALLOIMMUNITY; ALLOREACTIVE T CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL EXPANSION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ERYTHROID CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; KIDNEY GRAFT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; REGULATORY T LYMPHOCYTE; TH1 CELL; TH1 TH2 BALANCE; UPREGULATION; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; HISTOCOMPATIBILITY; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; METABOLISM; MIXED LYMPHOCYTE CULTURE; NONOBESE DIABETIC MOUSE; SCID MOUSE; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; CELL PROLIFERATION; CYTOKINE RECEPTOR COMMON BETA SUBUNIT; ERYTHROPOIETIN; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; ISOANTIGENS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, ERYTHROPOIETIN; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 84921646238     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013090945     Document Type: Article

References (39)

1. Nangaku M: Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J Am Soc Nephrol 17: 17-25, 2006
2. Choukroun G, Kamar N, Dussol B, Etienne I, Cassuto-Viguier E, Toupance O, Glowacki F, Moulin B, Lebranchu Y, Touchard G, Jaureguy M, Pallet N, Le Meur Y, Rostaing L, Martinez F; CAPRIT Study Investigators: Correction of postkidney transplant anemia reduces progression of allograft nephropathy. JAmSocNephrol23: 360-368, 2012
3. Pallet N, Bouvier N, Legendre C, Beaune P, Thervet E, Choukroun G, Martinez F: Antiapoptotic properties of recombinant human erythropoietin protects against tubular cyclosporine toxicity. Pharmacol Res 61: 71-75, 2010
4. Rocchetta F, Solini S, Mister M, Mele C, Cassis P, Noris M, Remuzzi G, Aiello S: Erythropoietin enhances immunostimulatory properties of immature dendritic cells. Clin Exp Immunol 165: 202-210, 2011
5. Cassis P, Gallon L, Benigni A, Mister M, Pezzotta A, Solini S, Gagliardini E, Cugini D, Abbate M, Aiello S, Rocchetta F, Scudeletti P, Perico N, Noris M, Remuzzi G: Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney Int 81: 903-918, 2012
6. Yuan R, Maeda Y, Li W, Lu W, Cook S, Dowling P: Erythropoietin: A potent inducer of peripheral immuno/inflammatory modulation in autoimmune EAE. PLoS ONE 3: e1924, 2008
7. Hirose S, Takahashi M, Ogawa R, Morimoto H, Izawa A, Sato H, Ise H, Hongo M, Ikeda U: Erythropoietin attenuates the development of experimental autoimmune myocarditis. Cardiovasc Drugs Ther 21: 17-27, 2007
8. Broxmeyer HE: Erythropoietin: Multiple targets, actions, and modifying influences for biological and clinical consideration. J Exp Med 210: 205-208, 2013
9. Kalland ME, Oberprieler NG, Vang T, Taskén K, Torgersen KM: T cellsignaling network analysis reveals distinct differences between CD28 and CD2 costimulation responses in various subsets and in the MAPK pathway between resting and activated regulatory T cells. J Immunol 187: 5233-5245, 2011
10. Acuto O, Michel F: CD28-mediated co-stimulation: A quantitative support for TCR signalling. Nat Rev Immunol 3: 939-951, 2003
11. Song J, Lei FT, Xiong X, Haque R: Intracellular signals of T cell costimulation. Cell Mol Immunol 5: 239-247, 2008
12. Benczik M, Gaffen SL: The interleukin (IL)-2 family cytokines: Survival and proliferation signaling pathways in T lymphocytes. Immunol Invest 33: 109-142, 2004
13. Ito R, Katano I, Kawai K, Hirata H, Ogura T, Kamisako T, Eto T, Ito M: Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation 87: 1654-1658, 2009
14. Brines M, Cerami A: Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise. Kidney Int 70: 246-250, 2006
15. Zhang YL, Radhakrishnan ML, Lu X, Gross AW, Tidor B, Lodish HF: Symmetric signaling by an asymmetric 1 erythropoietin: 2 erythropoietin receptor complex. Mol Cell 33: 266-274, 2009
16. Hand CC, Brines M: Promises and pitfalls in erythopoietin-mediated tissue protection: Are nonerythropoietic derivatives a way forward? J Investig Med 59: 1073-1082, 2011
17. van Rijt WG, Nieuwenhuijs-Moeke GJ, van Goor H, Jespersen B, Ottens PJ, Ploeg RJ, Leuvenink HG: ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury. J Transl Med 11: 9, 2013
18. Pulman KG, Smith M, Mengozzi M, Ghezzi P, Dilley A: The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model. Neuroscience 233: 174-183, 2013
19. Swartjes M, Morariu A, Niesters M, Brines M, Cerami A, Aarts L, Dahan A: ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: An experimental study in rats and b-common receptor knockout mice. Anesthesiology 115: 1084-1092, 2011
20. Lisowska KA, Bryl E, Witkowski JM: Erythropoietin receptor is detectable on peripheral blood lymphocytes and its expression increases in activated T lymphocytes. Haematologica 96: e12-e13, 2011
21. Lisowska KA, Debska-Slizien A, Bryl E, Rutkowski B, Witkowski JM: Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment. Artif Organs 34: 654-662, 2010
22. Lisowska KA, Frackowiak JE, Mikosik A, Witkowski JM: Changes in the expression of transcription factors involved in modulating the expression of EPO-R in activated human CD4-positive lymphocytes. PLoS ONE 8: e60326, 2013
23. Singh S, Verma R, Pradeep A, Leu K, Mortensen RB, Young PR, Oyasu M, Schatz PJ, Green JM, Wojchowski DM: Dynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR alleles. PLoS ONE 7: e29064, 2012
24. Bao H, Jacobs-Helber SM, Lawson AE, Penta K, Wickrema A, Sawyer ST: Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells). Blood 93: 3757-3773, 1999
25. Cheng G, Yu A, Malek TR: T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev 241: 63-76, 2011
26. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. NEnglJMed355: 2085-2098, 2006
27. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006
28. Cassis P, Azzollini N, Solini S, Mister M, Aiello S, Cugini D, Scudeletti P, Gagliardini E, Abbate M, Gallon L, Remuzzi G, Noris M: Both darbepoetin alfa and carbamylated erythropoietin prevent kidney graft dysfunction due to ischemia/reperfusion in rats. Transplantation 92: 271-279, 2011
29. Burne MJ, Daniels F, El Ghandour A, Mauiyyedi S, Colvin RB, O'Donnell MP, Rabb H: Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 108: 1283-1290, 2001
30. Nairz M, Schroll A, Moschen AR, Sonnweber T, Theurl M, Theurl I, Taub N, Jamnig C, Neurauter D, Huber LA, Tilg H, Moser PL, Weiss G: Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways. Immunity 34: 61-74, 2011
31. Choi D, Schroer SA, Lu SY, Wang L, Wu X, Liu Y, Zhang Y, Gaisano HY, Wagner KU, Wu H, Retnakaran R, Woo M: Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. JExp Med 207: 2831-2842, 2010
32. Cuzzocrea S, Mazzon E, di Paola R, Genovese T, Patel NS, Britti D, de Majo M, Caputi AP, Thiemermann C: Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse. Arthritis Rheum 52: 940-950, 2005
33. Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Möller B: Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol 28: 2430-2436, 2001
34. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials. Lancet 373: 1532-1542, 2009
35. Arcasoy MO: Erythropoiesis-stimulating agent use in cancer: Preclinical and clinical perspectives. Clin Cancer Res 14: 4685-4690, 2008
36. McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL: Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 76: 1718-1722, 1990
37. Wang C, Cordoba S, Hu M, Bertolino P, Bowen DG, Sharland AF, Allen RD, Alexander SI, McCaughan GW, Bishop GA: Spontaneous acceptance of mouse kidney allografts is associated with increased Foxp3 expression and differences in the B and T cell compartments. Transpl Immunol 24: 149-156, 2011
38. Krutzik P, Trejo A, Schulz K, Nolan G: Phospho flow cytometry methods for the analysis of kinase signaling in cell lines and primary human blood samples. In: Flow Cytometry Protocols, edited by Hawley TS, Hawley RG, Humana Press, New York, 2011, pp 179-202
39. Hagemeyer N, Boretius S, Ott C, Von Streitberg A, Welpinghus H, Sperling S, Frahm J, Simons M, Ghezzi P, Ehrenreich H: Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice. Mol Med 18: 628-635, 2012